Literature DB >> 29412780

Metastatic Prostate Cancer.

Oliver Sartor1, Johann S de Bono1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29412780     DOI： 10.1056/NEJMra1701695

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  101 in total

1.  Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.

Authors:  Pedro C Barata; Matthew Cooney; Prateek Mendiratta; Ruby Gupta; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2018-11-07       Impact factor: 3.850

Review 2.  Novel approaches to target the microenvironment of bone metastasis.

Authors:  Lorenz C Hofbauer; Aline Bozec; Martina Rauner; Franz Jakob; Sven Perner; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2021-04-19       Impact factor: 66.675

3.  Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Transl Androl Urol       Date:  2019-07

4.  New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.

Authors:  Ana F Castillo; Ulises D Orlando; Paula M Maloberti; Jesica G Prada; Melina A Dattilo; Angela R Solano; María M Bigi; Mayra A Ríos Medrano; María T Torres; Sebastián Indo; Graciela Caroca; Hector R Contreras; Belkis E Marelli; Facundo J Salinas; Natalia R Salvetti; Hugo H Ortega; Pablo Lorenzano Menna; Sergio Szajnman; Daniel E Gomez; Juan B Rodríguez; Ernesto J Podesta
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

5.  Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.

Authors:  Paymaneh D Malihi; Ryon P Graf; Angel Rodriguez; Naveen Ramesh; Jerry Lee; Ramsay Sutton; Rhett Jiles; Carmen Ruiz Velasco; Emi Sei; Anand Kolatkar; Christopher Logothetis; Nicholas E Navin; Paul Corn; Ana M Aparicio; Ryan Dittamore; James Hicks; Peter Kuhn; Amado J Zurita
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

Review 6.  [The role of systemic therapy of lung metastases with lymph node involvement].

Authors:  Y-D Ko
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

Review 7.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

8.  AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Authors:  Diogo A Bastos; Emmanuel S Antonarakis
Journal:  Precis Cancer Med       Date:  2018-09-18

9.  STK10 knockout inhibits cell migration and promotes cell proliferation via modulating the activity of ERM and p38 MAPK in prostate cancer cells.

Authors:  Lu Zhang; Shun-Yuan Lu; Rui Guo; Jin-Xia Ma; Ling-Yun Tang; Jin-Jin Wang; Chun-Ling Shen; Li-Ming Lu; Jie Liu; Zhu-Gang Wang; Hong-Xin Zhang
Journal:  Exp Ther Med       Date:  2021-06-08       Impact factor: 2.447

Review 10.  Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.

Authors:  Jose Mauricio Mota; Andrew J Armstrong; Steven M Larson; Josef J Fox; Michael J Morris
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-04-29       Impact factor: 5.554
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.